非重型血友病A的凝血因子VIII治疗史
基于INSIGHT研究,纳入1013例基线FVIII活性2-40 IU/dL的非重型血友病A患者,中位首次FVIII暴露年龄为3.7岁,且随基线FVIII活性升高而增大;亚组104例中位首次20次暴露年龄为10.2岁,年化出血率低,自发性大出血罕见。
要点
- 非重型血友病A患者首次FVIII暴露中位年龄为3.7岁(IQR 1.4-7.7)。
- 首次FVIII暴露年龄随基线FVIII活性升高而增大,2-5 IU/dL组为2.5岁,25-40 IU/dL组为9.7岁。
- 亚组中位年化出血率1.1,关节出血率0.3,自发性大出血率0。
核心结论
- 非重型血友病A中,首次FVIII暴露年龄随基线FVIII活性升高而增大,且自发性大出血罕见。
研究设计与样本
- 来自INSIGHT研究的队列分析,纳入基线FVIII活性2-40 IU/dL的非重型血友病患者,总队列n=1013,详细亚组n=104。
主要发现
- 总队列中位基线FVIII活性为8 IU/dL(IQR 4-15),中位首次FVIII暴露年龄为3.7岁(IQR 1.4-7.7)。
- 中位首次FVIII暴露年龄从FVIII活性2-5 IU/dL组的2.5岁(IQR 1.2-5.7)升至25-40 IU/dL组的9.7岁(IQR 4.8-16.0)。
- 亚组中位首次暴露年龄为4.0岁(IQR 1.4-7.6),第5次暴露为5.6岁(IQR 2.9-9.3),第10次为7.5岁(IQR 4.4-11.3),第20次为10.2岁(IQR 6.5-14.2)。
- 亚组中位年化全因出血率为1.1(IQR 0.5-2.6),关节出血率为0.3(IQR 0.1-0.7),自发性大出血率为0(IQR 0-0)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with non-severe hemophilia A, we lack detailed knowledge on the timing of treatment with factor VIII (FVIII) concentrates. This knowledge could provide information about the expected treatment timing in patients with severe hemophilia A treated with non-replacement therapies. OBJECTIVE: To assess the FVIII treatment history in patients with non-severe hemophilia A. METHODS: Patients with non-severe hemophilia (baseline FVIII activity [FVIII:C] 2-40 IU/dL) were included from the INSIGHT study. The primary outcome was median age at first FVIII exposure (ED1). In a subgroup of patients for whom more detailed information was available, we analyzed the secondary outcomes: median age at first 20 EDs, annualized bleeding rate for all bleeds (ABR), joint bleeds (AJBR), and major spontaneous bleeds (ASmBR). RESULTS: In the total cohort (n = 1013), median baseline FVIII activity was 8 IU/dL (interquartile range [IQR] 4-15) and the median age at ED1 was 3.7 years (IQR 1.4-7.7). Median age at ED1 rose from 2.5 years (IQR 1.2-5.7) in patients with FVIII:C 2-5 IU/dL to 9.7 years (IQR 4.8-16.0) in patients with FVIII:C 25-40 IU/dL. In the subgroup (n = 104), median age at ED1, ED5, ED10, and ED20 was 4.0 years (IQR 1.4-7.6), 5.6 years (IQR 2.9-9.3), 7.5 years (IQR 4.4-11.3), and 10.2 years (IQR 6.5-14.2), respectively. Median ABR, AJBR, and ASmBR were 1.1 (IQR 0.5-2.6), 0.3 (IQR 0.1-0.7), and 0 (IQR 0-0), respectively. CONCLUSION: This study demonstrates that in non-severe hemophilia A, the age at first FVIII exposure increases with baseline FVIII:C and that major spontaneous bleeds rarely occur.
引用
- Abdi A, Kloosterman FR, Eckhardt CL, et al. The factor VIII treatment history of non-severe hemophilia A. J Thromb Haemost. 2020. PMID: 32877570. doi:10.1111/jth.15076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。